ClinicalTrials.gg
CompletedNCT01109836ASPISUpdated Jan 13, 2015

Austrian Polyintervention Study to Prevent Cognitive Decline After Ischemic Stroke

A Phase 4 interventional study of Motivation and lifestyle intervention in Ischemic Stroke, Cognitive Decline and Dementia, sponsored by Danube University Krems. Completed at 5 sites in Austria. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-01-13.

Sponsored by Danube University Krems · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Ischemic Stroke with a site in Austria — 12 open to participants now, 15 under way, 1 of them phase 3. Ischemic Stroke · Austria.

Enrollment
22nd of 34
202 · median 447
Started
2010
with 2 others
Phase 4
5 of 49
1 open now
Registered
15th of 49
by date

Among the 49 studies in Ischemic Stroke with a site in Austria, this one is the 22nd largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2010, is one of 5 in phase 4, and was the 15th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

12 of the 49 studies in Ischemic Stroke with a site in Austria are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Ischemic Stroke with a site in Austria, or all of them as a file.
02

Study summary

Aim of this randomized controlled study is to test if intensive polyintervention therapy including life style modifications targeting at reduction of modifiable risk factors of stroke can reduce the risk of post-stroke cognitive decline compared to a group of patients receiving standard care.

Read the detailed description

Stroke is the second most frequent cause of death and cognitive deficits including dementia occur frequently following a stroke. The frequency of cognitive disturbances has been reported up to 30% and thus occurs three times more frequent than recurrent stroke (10%). Major attempts have been made to prevent the occurrence of new strokes by means of effective strategies including preventive drugs. In contrast, hardly any studies have been performed addressing the prevention of deteriorating cognitive function following a stroke. In spite of this high prevalence therapeutic possibilities are extremely limited. It must be expected that cognitive deficits become even a more frequent disability following stroke. This is caused by the increased aging of the population leading to further increase of incidence, furthermore that more people survive their acute stroke due to increased possibilities of acute treatment, and that frequent risk factors (e.g. hypertension, diabetes) are increasingly controlled, thus leading to less severe strokes with less severe and permanent motor deficits, but an increase of potentially disabling cognitive disturbances. The aim of this randomized controlled study is to test an intensive multiple intervention therapy for the first time in stroke and to add life style modifications targeting modifiable risk factors for cognitive deterioration.

It is hypothesized that the risk of post-stroke cognitive decline can be significantly reduced compared to a control group with standard care when using polyintervention. These interventions will focus on nutrition, exercise, cognitive and social activity and monitoring and management of metabolic and vascular risk factors. Regular contacts with the subjects shall increase motivation and adherence to the study protocol.

03

Conditions studied

  • Ischemic Stroke
  • Cognitive Decline
  • Dementia

Keywords

  • prevention
  • cognitive decline
  • post-stroke dementia
  • life-style intervention
  • vascular risk factors
  • polyintervention
  • multifactorial treatment
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic ischemic stroke with clinical syndrome of stroke and a corresponding ischemic lesion.
  • MRI or CT results compatible with clinical diagnosis of acute ischemic stroke
  • NIH Stroke Scale Score on admission 1 to 14, both inclusive
  • Modified Rankin Scale before stroke 0 to 2, inclusive
  • Randomization within 3 months after stroke onset (goal: 80% within 3 weeks)
  • Sufficient communication possible
  • given by the patient and/or the patient's legally acceptable representative

Exclusion criteria

Exclusion Criteria:

  • Substantial cognitive decline ( (MMSE) score > 24) or pre-existing dementia or Parkinson disease
  • Persistent disturbed level of consciousness
  • Persistent aphasia
  • Pre-existing significant psychiatric diseases (i.e. Schizophrenia, Major Depression, Bipolar Disorders, all according to DSMIV); Patients with minor Depression (DSM IV) can be included
  • Severe sensory impairment making neuropsychological testing impossible
  • Severe comorbidity (e.g. unstable or severe cardiovascular or pulmonal disease, neoplasm, severe liver or renal insufficiency and symptomatic stenosis of the ipsilateral carotid artery, cancer...)
  • Unreliability for follow up
  • Unwillingness or inability to participate or to sign the
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Motivation and lifestyle intervention

    Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.

    Behavioral: Motivation and lifestyle intervention

  • No intervention
    Control

    Standard stroke care

Interventions

  • BehavioralMotivation and lifestyle intervention

    Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.

06

What researchers measure

Primary outcomes

  1. Number of persons having cognitively declined at 24 months

    Cognitive decline is defined as a significant decline in the composite scores of at least 2 of 5 neuropsychologically tested domains (speed of mental processing, executive functions, working memory, memory, spatial constructive functions). The alpha level for the decision is 0.05.

    Time frame: 24 months after randomization

  2. Cognitive decline measured on the Cognitive Subscale of the Alzheimer's disease assessment scale (ADAS-cog) at 24 months

    Difference between the measures at baseline and at 24 months on the Cognitive Subscale of the Alzheimer's disease assessment scale (ADAS-cog).

    Time frame: 24 months after randomization

Secondary outcomes

  1. Number of persons having cognitively declined 12 months after randomization

    Cognitive decline is defined as a significant decline in the composite scores of at least 2 of 5 neuropsychologically tested domains (speed of mental processing, executive functions, working memory, memory, spatial constructive functions). The alpha level for the decision is 0.05.

    Time frame: 12 months after randomization

  2. Cognitive decline on the Cognitive Subscale of the Alzheimer's disease assessment scale (ADAS-cog) at 12 months

    Difference between the measures at baseline and at 12 months on the Cognitive Subscale of the Alzheimer's disease assessment scale (ADAS-cog).

    Time frame: 12 months after randomization

  3. Cognitive impairment on the Mini-Mental-State-Examination (MMSE) scale at 12 months

    Time frame: 12 months after randomization

  4. Cognitive impairment on the Mini-Mental-State-Examination (MMSE) scale at 24 months

    Time frame: 24 months after randomization

  5. Change in cognitive abilities measured by composite scores for each of 5 cognitive domains

    For each of the five cognitive domains (executive functions, working memory, general memory, speed of cognitive processing, visual spatial ability) standardized composite scores are calculated from the differences between baseline and 12 months in individual neuropsychological test results.

    Time frame: 12 months after randomization

  6. Composite outcome for vascular events

    vascular events include recurrent stroke, ACS, bypass surgery, PTA and vascular death

    Time frame: 24 months after randomization

  7. Neurological status on the National Institute of Health Stroke Scale (NIHSS) score

    Time frame: 12 months after randomization

  8. Functional status on the modified Rankin Scale

    Time frame: 12 months after randomization

  9. Activities of daily living on Barthel Index

    Time frame: 12 months after randomization

  10. Quality of life on the EQ-5D

    Time frame: 12 months after randomization

  11. Depression on the Center for Epidemiologic Studies Depression Scale (CESD)

    Time frame: 12 months after randomization

  12. All cause mortality

    Time frame: 24 months after randomization

  13. Change in cognitive abilities measured by composite scores for each of 5 cognitive domains

    For each of the five cognitive domains (executive functions, working memory, general memory, speed of cognitive processing, visual spatial ability) standardized composite scores are calculated from the differences between baseline and 24 months in individual neuropsychological test results.

    Time frame: 24 months after randomization

  14. Neurological status on the National Institute of Health Stroke Scale (NIHSS)score

    Time frame: 24 months after randomization

  15. Functional status on the modified Rankin Scale

    Time frame: 24 months after randomization

  16. Activities of daily living on Barthel Index

    Time frame: 24 months after randomization

  17. Quality of life on the EQ-5D

    Time frame: 24 months after randomization

  18. Depression on the Center for Epidemiologic Studies Depression Scale (CESD)

    Time frame: 24 months after randomization

07

Study locations

5 sites
  • Dept of Neurology Landesklinikum Waldviertel Horn / Allentsteig
    Horn, 3580, Austria
  • Dept of Neurology, Landesklinikum Mostviertel Amstetten-Mauer
    Mauer bei Amstetten, 3362, Austria
  • Dept. Neurology, LK St.Pölten
    St. Pölten, 3100, Austria
  • Dept of Neurology, Landesklinikum Donauregion Tulln
    Tulln, A-3430, Austria
  • Dept of Neurology, Landesklinikum Wr. Neustadt
    Wr. Neustadt, A-2700, Austria
08

References and documents

Publications

  • Matz K, Tuomilehto J, Teuschl Y, Dachenhausen A, Brainin M. Comparison of oral glucose tolerance test and HbA1c in detection of disorders of glucose metabolism in patients with acute stroke. Cardiovasc Diabetol. 2020 Dec 5;19(1):204. doi: 10.1186/s12933-020-01182-6. PubMed 33278898 ↗
  • Matz K, Teuschl Y, Firlinger B, Dachenhausen A, Keindl M, Seyfang L, Tuomilehto J, Brainin M; ASPIS Study Group. Multidomain Lifestyle Interventions for the Prevention of Cognitive Decline After Ischemic Stroke: Randomized Trial. Stroke. 2015 Oct;46(10):2874-80. doi: 10.1161/STROKEAHA.115.009992. Epub 2015 Sep 15. PubMed 26374482 ↗
  • Brainin M, Matz K, Nemec M, Teuschl Y, Dachenhausen A, Asenbaum-Nan S, Bancher C, Kepplinger B, Oberndorfer S, Pinter M, Schnider P, Tuomilehto J; ASPIS Study Group. Prevention of poststroke cognitive decline: ASPIS--a multicenter, randomized, observer-blind, parallel group clinical trial to evaluate multiple lifestyle interventions--study design and baseline characteristics. Int J Stroke. 2015 Jun;10(4):627-35. doi: 10.1111/ijs.12188. Epub 2013 Nov 10. PubMed 24206541 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2010
First posted
Apr 23, 2010
Start
Jun 2010
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Last update
Jan 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01109836
Lead sponsor
Danube University Krems
Collaborators
NÖ Forschungs- und Bildungsges.m.b.H (NFB)
First posted
Apr 23, 2010
Start date
Jun 2010
Primary completion
Nov 2014
Completion
Nov 2014
Last update
Jan 13, 2015

Study contacts

Michael Brainin, Prof. MD
principal investigator · Danube University Krems

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion